Napo Pharmaceuticals, Inc. Announces Publication of Paper on Crofelemer for Indication of Irritable Bowel Syndrome

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc., (“Napo”) announces that a paper entitled “Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients” (D-IBS) has been published in the Digestion – International Journal of Gastroenterology, 2008;78:180-186. The paper was authored by Allen W. Mangel, MD, PhD of RTI Health Solutions and Pravin Chaturvedi, PhD, President and CSO of Napo.

Back to news